Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
T-cell bispecific antibody
carcinoembryonic antigen T-cell bispecific antibody
combination
humanized mice
immunotherapy
programmed death–ligand 1
solid tumors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
01
2021
accepted:
12
01
2021
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
[This corrects the article .].
Identifiants
pubmed: 33614518
doi: 10.3389/fonc.2021.650149
pmc: PMC7887512
doi:
Types de publication
Published Erratum
Langues
eng
Pagination
650149Commentaires et corrections
Type : ErratumFor
Informations de copyright
Copyright © 2021 Sam, Colombetti, Fauti, Roller, Biehl, Fahrni, Nicolini, Perro, Nayak, Bommer, Schoenle, Karagianni, Le Clech, Steinhoff, Klein, Umaña and Bacac.